Regulation mechanism of Fbxw7-related signaling pathways (Review)

Zhou,Zhenyu; He,Chuanchao; Wang,Jie

doi:10.3892/or.2015.4227

Regulation mechanism of Fbxw7-related signaling pathways (Review)

Authors:
- Zhenyu Zhou
- Chuanchao He
- Jie Wang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China
Published online on: August 26, 2015 https://doi.org/10.3892/or.2015.4227
Pages: 2215-2224

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

F-box and WD repeat domain-containing 7 (Fbxw7), the substrate-recognition component of SCFFbxw7 complex, is thought to be a tumor suppressor involved in cell growth, proliferation, differentiation and survival. Although an increasing number of ubiquitin substrates of Fbxw7 have been identified, the best characterized substrates are cyclin E and c-Myc. Fbxw7/cyclin E and Fbxw7/c-Myc pathways are tightly regulated by multiple regulators. Fbxw7 has been identified as a tumor suppressor in hepatocellular carcinoma. This review focused on the regulation of Fbxw7/cyclin E and Fbxw7/c-Myc pathways and discussed findings to gain a better understanding of the role of Fbxw7 in hepatocellular carcinoma.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, et al CONCORD Working Group: Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 385:977–1010. 2015. View Article : Google Scholar
3	Adams J: Development of the proteasome inhibitor PS-341. Oncologist. 7:9–16. 2002. View Article : Google Scholar : PubMed/NCBI
4	Tu Y, Chen C, Pan J, Xu J, Zhou ZG and Wang CY: The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol. 5:726–738. 2012.PubMed/NCBI
5	Bedford L, Lowe J, Dick LR, Mayer RJ and Brownell JE: Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 10:29–46. 2011. View Article : Google Scholar
6	Voutsadakis IA: The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci. 19:672012. View Article : Google Scholar : PubMed/NCBI
7	Devoy A, Soane T, Welchman R and Mayer RJ: The ubiquitin-proteasome system and cancer. Essays Biochem. 41:187–203. 2005. View Article : Google Scholar : PubMed/NCBI
8	Komander D: The emerging complexity of protein ubiquitination. Biochem Soc Trans. 37:937–953. 2009. View Article : Google Scholar : PubMed/NCBI
9	Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem. 70:503–533. 2001. View Article : Google Scholar : PubMed/NCBI
10	Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al: Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 416:703–709. 2002. View Article : Google Scholar : PubMed/NCBI
11	Schulman BA, Carrano AC, Jeffrey PD, Bowen Z, Kinnucan ER, Finnin MS, Elledge SJ, Harper JW, Pagano M and Pavletich NP: Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature. 408:381–386. 2000. View Article : Google Scholar : PubMed/NCBI
12	Hartwell LH, Mortimer RK, Culotti J and Culotti M: Genetic control of the cell division cycle in yeast: V. genetic analysis of cdc mutants. Genetics. 74:267–286. 1973.PubMed/NCBI
13	Hubbard EJ, Wu G, Kitajewski J and Greenwald I: sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes Dev. 11:3182–3193. 1997. View Article : Google Scholar
14	Moberg KH, Bell DW, Wahrer DC, Haber DA and Hariharan IK: Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 413:311–316. 2001. View Article : Google Scholar : PubMed/NCBI
15	Welcker M and Clurman BE: FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 8:83–93. 2008. View Article : Google Scholar
16	Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B and Lengauer C: Inactivation of hCDC4 can cause chromosomal instability. Nature. 428:77–81. 2004. View Article : Google Scholar : PubMed/NCBI
17	Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M and Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer Res. 62:4535–4539. 2002.PubMed/NCBI
18	Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, et al: FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI
19	Davis H, Lewis A, Behrens A and Tomlinson I: Investigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines. Gut. 63:792–799. 2014. View Article : Google Scholar :
20	Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW and Elledge SJ: Phosphorylation-dependent ubiquitination of cyclin E by the SCF^Fbw7 ubiquitin ligase. Science. 294:173–177. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004. View Article : Google Scholar : PubMed/NCBI
22	Wei W, Jin J, Schlisio S, Harper JW and Kaelin WG Jr: The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 8:25–33. 2005. View Article : Google Scholar : PubMed/NCBI
23	O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 204:1813–1824. 2007. View Article : Google Scholar : PubMed/NCBI
24	Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al: SCF^FBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
25	Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R and Balmain A: FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 321:1499–1502. 2008. View Article : Google Scholar : PubMed/NCBI
26	Li J, Pauley AM, Myers RL, Shuang R, Brashler JR, Yan R, Buhl AE, Ruble C and Gurney ME: SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-beta peptide production. J Neurochem. 82:1540–1548. 2002. View Article : Google Scholar : PubMed/NCBI
27	Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, et al: Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell. 24:75–89. 2013. View Article : Google Scholar : PubMed/NCBI
28	Galli F, Rossi M, D'Alessandra Y, De Simone M, Lopardo T, Haupt Y, Alsheich-Bartok O, Anzi S, Shaulian E, Calabrò V, et al: MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. J Cell Sci. 123:2423–2433. 2010. View Article : Google Scholar : PubMed/NCBI
29	Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, Shibata K, Nakamura S, Kikuchi A and Kitagawa M: Fbw7 promotes ubiquitin-dependent degradation of c-Myb: Involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene. 28:2393–2405. 2009. View Article : Google Scholar : PubMed/NCBI
30	Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C and Lounsbury KM: Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia. J Cell Biochem. 112:3882–3890. 2011. View Article : Google Scholar : PubMed/NCBI
31	Liu Y, Tong Z, Li T, Chen Q, Zhuo L, Li W, Wu RC and Yu C: Hepatitis B virus X protein stabilizes amplified in breast cancer 1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness. Hepatology. 56:1015–1024. 2012. View Article : Google Scholar : PubMed/NCBI
32	Tu K, Zheng X, Yin G, Zan X, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. Mol Med Rep. 6:525–530. 2012.PubMed/NCBI
33	Pérez-Benavente B, García JL, Rodríguez MS, Pineda-Lucena A, Piechaczyk M, Font de Mora J and Farràs R: GSK3-SCF^FBXW7 targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase. Oncogene. 32:2189–2199. 2013. View Article : Google Scholar
34	Arabi A, Ullah K, Branca RM, Johansson J, Bandarra D, Haneklaus M, Fu J, Ariës I, Nilsson P, Den Boer ML, et al: Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. Nat Commun. 3:9762012. View Article : Google Scholar
35	Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A: Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 432:775–779. 2004. View Article : Google Scholar : PubMed/NCBI
36	Teng CL, Hsieh YC, Phan L, Shin J, Gully C, Velazquez-Torres G, Skerl S, Yeung SC, Hsu SL and Lee MH: FBXW7 is involved in Aurora B degradation. Cell Cycle. 11:4059–4068. 2012. View Article : Google Scholar : PubMed/NCBI
37	Zhao J, Tang J, Men W and Ren K: FBXW7-mediated degradation of CCDC6 is impaired by ATM during DNA damage response in lung cancer cells. FEBS Lett. 586:4257–4263. 2012. View Article : Google Scholar : PubMed/NCBI
38	Davis MA, Larimore EA, Fissel BM, Swanger J, Taatjes DJ and Clurman BE: The SCF-Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator. Genes Dev. 27:151–156. 2013. View Article : Google Scholar : PubMed/NCBI
39	Tan M, Zhao Y, Kim SJ, Liu M, Jia L, Saunders TL, Zhu Y and Sun Y: SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell. 21:1062–1076. 2011. View Article : Google Scholar : PubMed/NCBI
40	Wang R, Wang Y, Liu N, Ren C, Jiang C, Zhang K, Yu S, Chen Y, Tang H, Deng Q, et al: FBW7 regulates endothelial functions by targeting KLF2 for ubiquitination and degradation. Cell Res. 23:803–819. 2013. View Article : Google Scholar : PubMed/NCBI
41	Bialkowska AB, Liu Y, Nandan MO and Yang VW: A colon cancer-derived mutant of Krüppel-like factor 5 (KLF5) is resistant to degradation by glycogen synthase kinase 3β (GSK3β) and the E3 ubiquitin ligase F-box and WD repeat domain-containing 7α (FBW7α). J Biol Chem. 289:5997–6005. 2014. View Article : Google Scholar : PubMed/NCBI
42	Bengoechea-Alonso MT and Ericsson J: The ubiquitin ligase Fbxw7 controls adipocyte differentiation by targeting C/EBPalpha for degradation. Proc Natl Acad Sci USA. 107:11817–11822. 2010. View Article : Google Scholar : PubMed/NCBI
43	Balamurugan K, Sharan S, Klarmann KD, Zhang Y, Coppola V, Summers GH, Roger T, Morrison DK, Keller JR and Sterneck E: FBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4. Nat Commun. 4:16622013. View Article : Google Scholar
44	Biswas M, Phan D, Watanabe M and Chan JY: The Fbw7 tumor suppressor regulates nuclear factor E2-related factor 1 transcription factor turnover through proteasome-mediated proteolysis. J Biol Chem. 286:39282–39289. 2011. View Article : Google Scholar : PubMed/NCBI
45	Lochab S, Pal P, Kapoor I, Kanaujiya JK, Sanyal S, Behre G and Trivedi AK: E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation. Biochim Biophys Acta. 1833:2639–2652. 2013. View Article : Google Scholar : PubMed/NCBI
46	Yumimoto K, Matsumoto M, Onoyama I, Imaizumi K and Nakayama KI: F-box and WD repeat domain-containing-7 (Fbxw7) protein targets endoplasmic reticulum-anchored osteogenic and chondrogenic transcriptional factors for degradation. J Biol Chem. 288:28488–28502. 2013. View Article : Google Scholar : PubMed/NCBI
47	Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM and Chen CS: Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells. Hepatology. 53:148–159. 2011. View Article : Google Scholar : PubMed/NCBI
48	Bengoechea-Alonso MT and Ericsson J: Tumor suppressor Fbxw7 regulates TGFβ signaling by targeting TGIF1 for degradation. Oncogene. 29:5322–5328. 2010. View Article : Google Scholar : PubMed/NCBI
49	Sun Y and Li X: The canonical wnt signal restricts the glycogen synthase kinase 3/fbw7-dependent ubiquitination and degradation of eya1 phosphatase. Mol Cell Biol. 34:2409–2417. 2014. View Article : Google Scholar : PubMed/NCBI
50	Kitagawa K, Shibata K, Matsumoto A, Matsumoto M, Ohhata T, Nakayama KI, Niida H and Kitagawa M: Fbw7 targets GATA3 through cyclin-dependent kinase 2-dependent proteolysis and contributes to regulation of T-cell development. Mol Cell Biol. 34:2732–2744. 2014. View Article : Google Scholar : PubMed/NCBI
51	Dai X, North BJ and Inuzuka H: Negative regulation of DAB2IP by Akt and SCF^Fbw7 pathways. Oncotarget. 5:3307–3315. 2014. View Article : Google Scholar : PubMed/NCBI
52	Trausch-Azar JS, Abed M, Orian A and Schwartz AL: Isoform-specific SCF^Fbw7 ubiquitination mediates differential regulation of PGC-1α. J Cell Physiol. 230:842–852. 2015. View Article : Google Scholar
53	Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C, Yao Y and Q: Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 13:1102014. View Article : Google Scholar : PubMed/NCBI
54	Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M and Harper JW: Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 18:2573–2580. 2004. View Article : Google Scholar : PubMed/NCBI
55	Sterian A, Kan T, Berki AT, Mori Y, Olaru A, Schulmann K, Sato F, Wang S, Paun B, Cai K, et al: Mutational and LOH analyses of the chromosome 4q region in esophageal adenocarcinoma. Oncology. 70:168–172. 2006. View Article : Google Scholar : PubMed/NCBI
56	van Drogen F, Sangfelt O, Malyukova A, Matskova L, Yeh E, Means AR and Reed SI: Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol Cell. 23:37–48. 2006. View Article : Google Scholar : PubMed/NCBI
57	Matsumoto A, Tateishi Y, Onoyama I, Okita Y, Nakayama K and Nakayama KI: Fbxw7β resides in the endoplasmic reticulum membrane and protects cells from oxidative stress. Cancer Sci. 102:749–755. 2011. View Article : Google Scholar : PubMed/NCBI
58	Ren H, Zhao L, Li Y, Yue P, Deng X, Owonikoko TK, Chen M, Khuri FR and Sun SY: The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett. 338:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
59	Embi N, Rylatt DB and Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 107:519–527. 1980. View Article : Google Scholar : PubMed/NCBI
60	Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9:2431–2438. 1990.PubMed/NCBI
61	Wu D and Pan W: GSK3: A multifaceted kinase in Wnt signaling. Trends Biochem Sci. 35:161–168. 2010. View Article : Google Scholar :
62	Kim L and Kimmel AR: GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev. 10:508–514. 2000. View Article : Google Scholar : PubMed/NCBI
63	Buttrick GJ and Wakefield JG: PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle. 7:2621–2625. 2008. View Article : Google Scholar : PubMed/NCBI
64	Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, Clurman BE and Roberts JM: Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell. 12:381–392. 2003. View Article : Google Scholar : PubMed/NCBI
65	Hao B, Oehlmann S, Sowa ME, Harper JW and Pavletich NP: Structure of a Fbw7-Skp1-cyclin E complex: Multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell. 26:131–143. 2007. View Article : Google Scholar : PubMed/NCBI
66	Bahram F, von der Lehr N, Cetinkaya C and Larsson LG: c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 95:2104–2110. 2000.PubMed/NCBI
67	Tan Y, Sangfelt O and Spruck C: The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett. 271:1–12. 2008. View Article : Google Scholar : PubMed/NCBI
68	Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O and Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 413:316–322. 2001. View Article : Google Scholar : PubMed/NCBI
69	Ye X, Nalepa G, Welcker M, Kessler BM, Spooner E, Qin J, Elledge SJ, Clurman BE and Harper JW: Recognition of phosphodegron motifs in human cyclin E by the SCF^Fbw7 ubiquitin ligase. J Biol Chem. 279:50110–50119. 2004. View Article : Google Scholar : PubMed/NCBI
70	Welcker M and Clurman BE: Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div. 2:72007. View Article : Google Scholar : PubMed/NCBI
71	Geng Y, Lee YM, Welcker M, Swanger J, Zagozdzon A, Winer JD, Roberts JM, Kaldis P, Clurman BE and Sicinski P: Kinase-independent function of cyclin E. Mol Cell. 25:127–139. 2007. View Article : Google Scholar : PubMed/NCBI
72	Siu KT, Rosner MR and Minella AC: An integrated view of cyclin E function and regulation. Cell Cycle. 11:57–64. 2012. View Article : Google Scholar :
73	Minella AC, Grim JE, Welcker M and Clurman BE: p53 and SCF^Fbw7 cooperatively restrain cyclin E-associated genome instability. Oncogene. 26:6948–6953. 2007. View Article : Google Scholar : PubMed/NCBI
74	Minella AC, Swanger J, Bryant E, Welcker M, Hwang H and Clurman BE: p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol. 12:1817–1827. 2002. View Article : Google Scholar : PubMed/NCBI
75	Kimura T, Gotoh M, Nakamura Y and Arakawa H: hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94:431–436. 2003. View Article : Google Scholar : PubMed/NCBI
76	Mandal S, Freije WA, Guptan P and Banerjee U: Metabolic control of G1-S transition: Cyclin E degradation by p53-induced activation of the ubiquitin-proteasome system. J Cell Biol. 188:473–479. 2010. View Article : Google Scholar : PubMed/NCBI
77	Finkin S, Aylon Y, Anzi S, Oren M and Shaulian E: Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene. 27:4411–4421. 2008. View Article : Google Scholar : PubMed/NCBI
78	Guo Z, Zhou Y, Evers BM and Wang Q: Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. Biochem Biophys Res Commun. 418:426–432. 2012. View Article : Google Scholar : PubMed/NCBI
79	Wang H, Zhang X, Geng L, Teng L and Legerski RJ: Artemis regulates cell cycle recovery from the S phase checkpoint by promoting degradation of cyclin E. J Biol Chem. 284:18236–18243. 2009. View Article : Google Scholar : PubMed/NCBI
80	Welcker M and Clurman BE: The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol Chem. 280:7654–7658. 2005. View Article : Google Scholar
81	Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 14:1296–1302. 2004. View Article : Google Scholar : PubMed/NCBI
82	Poinsignon C, de Chasseval R, Soubeyrand S, Moshous D, Fischer A, Haché RJ and de Villartay JP: Phosphorylation of Artemis following irradiation-induced DNA damage. Eur J Immunol. 34:3146–3155. 2004. View Article : Google Scholar : PubMed/NCBI
83	Ahuja D, Sáenz-Robles MT and Pipas JM: SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene. 24:7729–7745. 2005. View Article : Google Scholar : PubMed/NCBI
84	Minella AC, Welcker M and Clurman BE: Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci USA. 102:9649–9654. 2005. View Article : Google Scholar : PubMed/NCBI
85	Hynes NE and Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
86	Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AA, Wohlschlegel J, Widschwendter M and Spruck C: PP2A-B55β antagonizes cyclin E1 proteolysis and promotes its dysregulation in cancer. Cancer Res. 74:2006–2014. 2014. View Article : Google Scholar : PubMed/NCBI
87	Bhaskaran N, van Drogen F, Ng HF, Kumar R, Ekholm-Reed S, Peter M, Sangfelt O and Reed SI: Fbw7α and Fbw7γ collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation. Mol Cell Biol. 33:85–97. 2013. View Article : Google Scholar :
88	Reed SI: Cooperation between different Cdc4/Fbw7 isoforms may be associated with 2-step inactivation of SCFCdc4 targets. Cell Cycle. 5:1923–1924. 2006. View Article : Google Scholar : PubMed/NCBI
89	Zhang W, MacDonald EM and Koepp DM: The stomatin-like protein SLP-1 and Cdk2 interact with the F-Box protein Fbw7-γ. PLoS One. 7:e477362012. View Article : Google Scholar
90	Schülein C, Eilers M and Popov N: PI3K-dependent phosphorylation of Fbw7 modulates substrate degradation and activity. FEBS Lett. 585:2151–2157. 2011. View Article : Google Scholar : PubMed/NCBI
91	Sim KG, Zang Z, Yang CM, Bonventre JV and Hsu SI: TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability. Cell Cycle. 3:1296–1304. 2004. View Article : Google Scholar : PubMed/NCBI
92	Cizmecioglu O, Krause A, Bahtz R, Ehret L, Malek N and Hoffmann I: Plk2 regulates centriole duplication through phosphorylation-mediated degradation of Fbxw7 (human Cdc4). J Cell Sci. 125:981–992. 2012. View Article : Google Scholar : PubMed/NCBI
93	Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, et al: The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med. 210:1545–1557. 2013. View Article : Google Scholar : PubMed/NCBI
94	Keck JM, Summers MK, Tedesco D, Ekholm-Reed S, Chuang LC, Jackson PK and Reed SI: Cyclin E overexpression impairs progression through mitosis by inhibiting APC^Cdh1. J Cell Biol. 178:371–385. 2007. View Article : Google Scholar : PubMed/NCBI
95	Lau AW, Inuzuka H, Fukushima H, Wan L, Liu P, Gao D, Sun Y and Wei W: Regulation of APC^Cdh1 E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7. Cell Res. 23:947–961. 2013. View Article : Google Scholar : PubMed/NCBI
96	Meyer N and Penn LZ: Reflecting on 25 years with MyC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
97	Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alborán IM, Nakayama K and Nakayama KI: Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med. 204:2875–2888. 2007. View Article : Google Scholar : PubMed/NCBI
98	Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 101:9085–9090. 2004. View Article : Google Scholar : PubMed/NCBI
99	Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2501–2514. 2000. View Article : Google Scholar : PubMed/NCBI
100	Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al: A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 6:308–318. 2004. View Article : Google Scholar : PubMed/NCBI
101	Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A, Tokarz S, Morgan C and Sears RC: The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J. 28:500–512. 2009. View Article : Google Scholar : PubMed/NCBI
102	Liu L and Eisenman RN: Regulation of c-Myc protein abundance by a protein phosphatase 2A-glycogen synthase kinase 3β-negative feedback pathway. Genes Cancer. 3:23–36. 2012. View Article : Google Scholar : PubMed/NCBI
103	Seo HR, Kim J, Bae S, Soh JW and Lee YS: Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J Biol Chem. 283:15601–15610. 2008. View Article : Google Scholar : PubMed/NCBI
104	Sjostrom SK, Finn G, Hahn WC, Rowitch DH and Kenney AM: The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell. 9:327–338. 2005. View Article : Google Scholar : PubMed/NCBI
105	Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62. 2007. View Article : Google Scholar : PubMed/NCBI
106	Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG and Colombo E: Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 182:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
107	Welcker M, Orian A, Grim JE, Eisenman RN and Clurman BE: A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol. 14:1852–1857. 2004. View Article : Google Scholar : PubMed/NCBI
108	Chandra S, Priyadarshini R, Madhavan V, Tikoo S, Hussain M, Mudgal R, Modi P, Srivastava V and Sengupta S: Enhancement of c-Myc degradation by BLM helicase leads to delayed tumor initiation. J Cell Sci. 126:3782–3795. 2013. View Article : Google Scholar : PubMed/NCBI
109	Tikoo S and Sengupta S: Time to bloom. Genome Integr. 1:142010. View Article : Google Scholar : PubMed/NCBI
110	Kim BY, Yang JS, Kwak SY, Zhang XK and Han YH: NEMO stabilizes c-Myc through direct interaction in the nucleus. FEBS Lett. 584:4524–4530. 2010. View Article : Google Scholar : PubMed/NCBI
111	Huang H, Ma L, Li J, Yu Y, Zhang D, Wei J, Jin H, Xu D, Gao J and Huang C: NF-κB1 inhibits c-Myc protein degradation through suppression of FBW7 expression. Oncotarget. 5:493–505. 2014. View Article : Google Scholar : PubMed/NCBI
112	Chen J, Shin JH, Zhao R, Phan L, Wang H, Xue Y, Post SM, Ho Choi H, Chen JS, Wang E, et al: CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun. 5:53842014. View Article : Google Scholar : PubMed/NCBI
113	Olive V, Sabio E, Bennett MJ, De Jong CS, Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A, et al: A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. eLife. 2:e008222013. View Article : Google Scholar : PubMed/NCBI
114	Onoyama I, Suzuki A, Matsumoto A, Tomita K, Katagiri H, Oike Y, Nakayama K and Nakayama KI: Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest. 121:342–354. 2011. View Article : Google Scholar :
115	Tu K, Zheng X, Zan X, Han S, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
116	Tu K, Zheng X, Zhou Z, Li C, Zhang J, Gao J, Yao Y and Liu Q: Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS One. 8:e685742013. View Article : Google Scholar : PubMed/NCBI
117	Imura S, Tovuu LO, Utsunomiya T, Morine Y, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, et al: The role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. J Gastroenterol Hepatol. 29:1822–1829. 2014. View Article : Google Scholar : PubMed/NCBI
118	Tien JC and Xu J: Steroid receptor coactivator-3 as a potential molecular target for cancer therapy. Expert Opin Ther Targets. 16:1085–1096. 2012. View Article : Google Scholar : PubMed/NCBI
119	Chen T, Sun Y, Ji P, Kopetz S and Zhang W: Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. Oct 20–2014.Epub ahead of print. View Article : Google Scholar
120	Piccolo S, Dupont S and Cordenonsi M: The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev. 94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
121	Lahusen T, Henke RT, Kagan BL, Wellstein A and Riegel AT: The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat. 116:225–237. 2009. View Article : Google Scholar : PubMed/NCBI